Biden pledged to allocate 80 million doses of the COVID-19 vaccine supply belonging to the U.S. by the end of June to aid the global fight against the pandemic. Earlier this month, the administration announced the plan for the first 25 million doses that the U.S. has begun shipping, with the remaining 55 million doses announced today.
Get the full story at our sister site, Pharmaceutical Processing World.
The White House scrapped plans to hold a Wednesday meeting at a Baltimore-based vaccine plant from Emergent BioSolutions following an exposé from The New York Times.
The Biden administration also announced plans to conduct an audit of the Strategic National Stockpile after the publication of the article, which described how the biopharmaceutical company lobbied the federal government to buy millions of anthrax vaccine doses.
Over the past ten years, the U.S. government has devoted almost half of its stockpile budget to BioSolutions’ anthrax vaccine, leaving a dearth of funding for pandemic response.
Get the full story from our sister site, Pharmaceutical Processing World.
Multiple reports have said President Trump will announce a $750 million deal with Abbott (NYSE:ABT) for 150 million of its rapid COVID-19 antigen tests.
As first reported by Politico before being confirmed by other outlets, a White House official said that Trump will announce the deal tonight, using his speech at the Republican National Convention to confirm the news.
The U.S. Department of Health and Human Services confirmed the reports in a news release late Thursday. Trump spoke for more than an hour at the RNC but did not make an announcement related to the deal with Abbott.
“This is a major development that will help our country to remain open, get Americans back to work, and kids back to school,” White House communications director Alyssa Farah said in a statement to CNBC. “The Trump Administration is proud to partner with Abbott Labs to make this purchase possible to help the American people.”
“The introduction of Abbott’s antigen test is a…